Ciliochoroidal Melanomas Treated With a Narrow Medical Proton Beam

Brovkina, A F; Zarubei, Georgy D.

doi:10.1001/archopht.1986.01050150102037

Cited by 48 publications

(18 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…107 The proton energy is variable between 70 and 200 MeV. 108 • 109 About 2000 oncological, neurosurgical, ophthalmological, 110 and endocrinological patients have been treated. 111 • 113 In 1989, the reconstructionof a 680-MeV cyclotron was fmished at the Joint Institute of Nuclear Research (JINR) in Dubna, 114 and patients have been treated using a degraded proton beam.…”

Section: Ibl On-going Proton and Helium-ion Trialsmentioning

confidence: 38%

Instrumentation for treatment of cancer using proton and light-ion beams

Chu

Ludewigt

Renner

1993

Review of Scientific Instruments

286

186

View full text Add to dashboard Cite

Clinical trials using accelerated heavy charged-particle beams for treating cancer and other diseases have been performed for nearly four decades. Recently there have been worldwide efforts to construct hospital-based medically dedicated proton or light-ion accelerator facilities. To make such accelerated heavy charged-particle beams clinically useful, specialized instruments must be developed to modify the physical characteristics of the particle beams in order to optimize their biological and clinical effects. This article reviews the beam modifying devices and associated dosimetric equipment developed specifically for controlling and monitoring the clinical beams.

show abstract

Section: Ibl On-going Proton and Helium-ion Trialsmentioning

confidence: 38%

Instrumentation for treatment of cancer using proton and light-ion beams

Chu

Ludewigt

Renner

1993

Review of Scientific Instruments

286

186

View full text Add to dashboard Cite

show abstract

“…The anatomy of the rabbit optic nerve and the behavior of its nerve fibers in the context of demyelinization and remyelinization have been studied extensively in the rabbit [12, 13, 14], facilitating comparison of our data with the literature. Furthermore, we have used the same treatment parameters as for the treatment of malignant melanomas in man with an accelerated proton beam [2, 3, 4, 5, 15, 16, 17, 18]. In addition, most cases, which have been reported in the literature, were investigated with histology only after radiation neuropathy had already become clinically visible.…”

Section: Discussionsupporting

confidence: 42%

Subclinical Experimental Optic Neuropathy after Accelerated Proton Beam Irradiation

et al. 2002

View full text Add to dashboard Cite

Background: Accelerated proton beam irradiation has been used for several years to treat intraocular tumors. The pathophysiology of proton-beam-induced retinopathy and neuropathy has not been characterized to date. The present study investigates the early effects of irradiation with an accelerated proton beam on the optic nerve of the rabbit. Materials and Methods: The optic nerve head of Albino New Zealand rabbits (n = 14) was irradiated with a narrow beam of accelerated protons using the total dose of 60 and 43 Gy, respectively. This dose was split up into 4 equal sessions taking place on 4 consecutive days. Ophthalmoscopic examination was performed regularly, and the rabbits were sacrificed at 1, 3 and 8 months after irradiation. The eyes were enucleated and processed for light and electron microscopy. Results: Despite the absence of ophthalmoscopically detectable optic neuropathy in all 14 rabbits irrespective of the dose of irradiation, light and electron microscopy of the optic nerve showed a glial and fibrotic perivascular scar made up predominantly of altered astrocytes. This scar formation was seen as early as 1 month after irradiation and was at times accompanied by infiltration with inflammatory cells perivascularly both outside and within the optic nerve. In contrast to the astrocytes, oligodendrocytes did not show degenerative cellular alterations. During the 8-month follow-up, no signs of vascular occlusion were found. Conclusions: The observed lesions in the glial tissues with consecutive fibrosis appear to stem from a direct effect of irradiation. This may represent the initial mechanism of early subclinical irradiation-induced damage to the optic nerve before vascular occlusions may occur at a later stage, which may lead to more severe damage.

show abstract

“…-72% [13]. Среди гистологических типов меланомы, как во всей группе обследованных лиц, так и среди умерших, преобладала смешанноклеточная форма (68,8% и 59,3%, соответственно), наиболее неблагоприятная в отноше-нии метастазирования и витального прогноза, что соот-ветствует данным других авторов [2,3]. Достоверно он-кологическая причина смерти имела место лишь в трети случаев.…”

Section: заключениеunclassified

“…Среди всех первичных внутриглазных злокачественных опухо-лей на долю меланомы сосудистого тракта приходится 88% [2]. В России заболеваемость увеальной меланомой по обращению в различных регионах колеблется от 6 до 13 человек на 1 млн взрослого населения [3]. Чаще всего заболевание проявляется в возрасте 30-80 лет (пик за-болеваемости приходится на 5-6-е десятилетие жизни), однако в последние десятилетия наблюдается тенденция к ее «омоложению» [3].…”

unclassified

“…В России заболеваемость увеальной меланомой по обращению в различных регионах колеблется от 6 до 13 человек на 1 млн взрослого населения [3]. Чаще всего заболевание проявляется в возрасте 30-80 лет (пик за-болеваемости приходится на 5-6-е десятилетие жизни), однако в последние десятилетия наблюдается тенденция к ее «омоложению» [3]. Среди методов лечения данной опухоли выделяют органосохранные (хирургическое вмешательство, лучевая терапия) и ликвидационные (энуклеация глазного яблока, экзентерация орбиты) [4].…”

unclassified

See 1 more Smart Citation